A phase Ib trial with a 4-week subcutaneous administration of either 10 mg or 15 mg tirzepatide once weekly in subjects with T2D led to a significant reduction in fasting plasma glucose concentrations (LSM difference [95% CI]: 49.12 mg/dl [78.14, 20.12] and 43.15 mg/dl [73.06, 13.21], respectively) and to reductions in body weight (LSM difference [95% CI]: 2.62 kg [3.79, 1.45] and 2.07 kg [3.25, 0.88], respectively
doi: 10.1016/j.celrep.2020.108683
Oncotarget 5 , 50765086 (2014)
Molecules 22 , 1388 (2017)
Zepbound through Eli Lillys direct self-pay program (called LillyDirect) is currently one of the most accessible brand-name GLP-1 options without insurance
It increases sperm count, motility, straight-swimming ability, as well as total normal sperm forms